LGR5 and neoplasm: were able to establish a measure (which was defined as the time CAR-Ts needed to enforce tumoricidal reactions against 50% of the target tumor cells) to opt for a certain LGR5-redirected CAR-T product as their therapeutic candidate for clinical assessment (called CNA3103) (62).